金斯瑞生物科技(01548)：CARVYKTI®于截至2025年9月30日止季度产生贸易销售净额约5.24亿美元

Core Insights - Kingsray Biotechnology (01548) announced that CARVYKTI® is expected to generate net trade sales of approximately $524 million for the quarter ending September 30, 2025, based on the collaboration and licensing agreement established with Legend and Janssen Biotech, Inc. on December 21, 2017 [1] Group 1 - Kingsray Biotechnology's CARVYKTI® is projected to achieve significant sales figures, indicating strong market potential [1] - The collaboration with Janssen Biotech, Inc. highlights strategic partnerships in the biotechnology sector [1] - The timeline for the projected sales extends to the end of Q3 2025, suggesting a long-term outlook for revenue generation [1]